Olympiad Research LP Makes New Investment in Cryoport, Inc. (NASDAQ:CYRX)

Olympiad Research LP purchased a new stake in shares of Cryoport, Inc. (NASDAQ:CYRX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 13,222 shares of the company’s stock, valued at approximately $103,000.

Other large investors have also recently modified their holdings of the company. Rhumbline Advisers increased its holdings in Cryoport by 2.9% during the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after purchasing an additional 1,764 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Cryoport by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after buying an additional 2,226 shares in the last quarter. Penbrook Management LLC increased its stake in shares of Cryoport by 6.0% during the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company’s stock valued at $409,000 after buying an additional 2,975 shares during the period. Avanza Fonder AB bought a new stake in shares of Cryoport in the fourth quarter valued at about $64,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Cryoport in the third quarter worth about $82,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Trading Up 1.8 %

NASDAQ:CYRX opened at $6.33 on Tuesday. The stock has a market capitalization of $312.90 million, a price-to-earnings ratio of -1.87 and a beta of 1.59. Cryoport, Inc. has a 52 week low of $5.32 and a 52 week high of $20.10. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $7.62 and a 200 day moving average of $7.75.

Analysts Set New Price Targets

A number of research firms have commented on CYRX. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Friday, January 17th. Roth Mkm cut their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Guggenheim started coverage on shares of Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.29.

Insider Transactions at Cryoport

In related news, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now directly owns 59,497 shares in the company, valued at $443,847.62. The trade was a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.10% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.